[
  {
    "ts": "2025-11-14T00:07:43+00:00",
    "headline": "Merck nears deal for flu-prevention biotech Cidara",
    "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
    "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "feb600a5-727c-382c-96f3-701294a4a06c",
      "content": {
        "id": "feb600a5-727c-382c-96f3-701294a4a06c",
        "contentType": "STORY",
        "title": "Merck nears deal for flu-prevention biotech Cidara",
        "description": "",
        "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
        "pubDate": "2025-11-14T00:07:43Z",
        "displayTime": "2025-11-14T00:07:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T04:20:22+00:00",
    "headline": "Merck (MRK) Delivers Strong Q3 2025 Earnings as Oncology Sales Drive Revenue Growth",
    "summary": "Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing better-than-expected financial results despite uneven product portfolio performance. The company’s revenue of $17.3 billion crossed analyst estimates of $16.98 billion, while its EPS […]",
    "url": "https://finance.yahoo.com/news/merck-mrk-delivers-strong-q3-042022417.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ab230763-a948-3ac0-b59c-ca92269a19fb",
      "content": {
        "id": "ab230763-a948-3ac0-b59c-ca92269a19fb",
        "contentType": "STORY",
        "title": "Merck (MRK) Delivers Strong Q3 2025 Earnings as Oncology Sales Drive Revenue Growth",
        "description": "",
        "summary": "Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing better-than-expected financial results despite uneven product portfolio performance. The company’s revenue of $17.3 billion crossed analyst estimates of $16.98 billion, while its EPS […]",
        "pubDate": "2025-11-14T04:20:22Z",
        "displayTime": "2025-11-14T04:20:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7f572bd67da146fcf0c740d8b0a50bb6",
          "originalWidth": 375,
          "originalHeight": 375,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6vTDauMGAVR2c3f8Np70vg--~B/aD0zNzU7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7f572bd67da146fcf0c740d8b0a50bb6.cf.webp",
              "width": 375,
              "height": 375,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/68elpyOJAayKU37_DKuoww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7f572bd67da146fcf0c740d8b0a50bb6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-delivers-strong-q3-042022417.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-delivers-strong-q3-042022417.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T00:07:43+00:00",
    "headline": "Merck nears $9.2bn deal for flu-prevention biotech Cidara",
    "summary": "Merck is nearing a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu,...",
    "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "feb600a5-727c-382c-96f3-701294a4a06c",
      "content": {
        "id": "feb600a5-727c-382c-96f3-701294a4a06c",
        "contentType": "STORY",
        "title": "Merck nears $9.2bn deal for flu-prevention biotech Cidara",
        "description": "",
        "summary": "Merck is nearing a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu,...",
        "pubDate": "2025-11-14T00:07:43Z",
        "displayTime": "2025-11-14T00:07:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nears-deal-flu-treatment-232344334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-14T09:30:00+00:00",
    "headline": "Recombinant Human Fibroblast Growth Factor Global Market Forecast 2025-2030: Markets Benefit from Strategic Investments and Collaborations",
    "summary": "Recombinant human fibroblast growth factors offer growth prospects in regenerative medicine and cosmetics, driven by efficient production systems. Key opportunities arise from applications in wound healing, tissue engineering, and cosmetics. Notable firms include Thermo Fisher and Merck.Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The \"Recombinant Human Fibroblast Growth Factor Market - Global Forecast 2025-2030\" report has been added to ResearchAndMarkets.com's offering. Recombinant human fibrobla",
    "url": "https://finance.yahoo.com/news/recombinant-human-fibroblast-growth-factor-093000334.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "fa2fb38e-b20d-38f2-9b85-dde3215bfff9",
      "content": {
        "id": "fa2fb38e-b20d-38f2-9b85-dde3215bfff9",
        "contentType": "STORY",
        "title": "Recombinant Human Fibroblast Growth Factor Global Market Forecast 2025-2030: Markets Benefit from Strategic Investments and Collaborations",
        "description": "",
        "summary": "Recombinant human fibroblast growth factors offer growth prospects in regenerative medicine and cosmetics, driven by efficient production systems. Key opportunities arise from applications in wound healing, tissue engineering, and cosmetics. Notable firms include Thermo Fisher and Merck.Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The \"Recombinant Human Fibroblast Growth Factor Market - Global Forecast 2025-2030\" report has been added to ResearchAndMarkets.com's offering. Recombinant human fibrobla",
        "pubDate": "2025-11-14T09:30:00Z",
        "displayTime": "2025-11-14T09:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/recombinant-human-fibroblast-growth-factor-093000334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/recombinant-human-fibroblast-growth-factor-093000334.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TMO"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]